Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing attractiveness of Switzerland as a pharmaceutical investment destination.
Attractive conditions must be maintained both for the large pharmaceutical companies - which are well established in Switzerland, but for which the Swiss domestic market is not so important for their total turnover - and for small and medium-sized companies that produce and distribute pharmaceutical products
